✦ LIBER ✦

177 - Phase II study of interferon gamma (rIFN-G) and vinblastine(VBL) in patients with advanced renal cell carcinoma (RCC)

✍ Scribed by C. Bacoyiannis; M.A. Dimopoulos; C. Nicolaides; G. Aravantinos; N. Xiros; D. Skarlos; N. Pavlidis; P. Kosmidis

Book ID: 117664436
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 219 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)84565-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of vinblastine in combi

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma

✍ Jordan Berlin; A. Christie King; Kendra Tutsch; John W. Findlay; Peter Kohler; M 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 447 KB

EORTC (30885) randomised phase III study

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma

✍ De Mulder, PHM; Oosterhof, G; Bouffioux, C; van Oosterom, AT; Vermeylen, K; Sylv 📂 Article 📅 1995 🏛 Nature Publishing Group 🌐 English ⚖ 982 KB

Phase II Trial of Pegylated Interferon-α

Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma

✍ Darren R. Feldman; G. Varuni Kondagunta; Lawrence Schwartz; Sujata Patil; Nicole 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 126 KB

A Phase II study of irinotecan in patien

A Phase II study of irinotecan in patients with advanced renal cell carcinoma

✍ Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

49LBA Final results of a Phase II random

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

✍ P. Mulders; R. Hawkins; P. Nathan; I. de Jong; S. Osanto; E. Porfiri; A. Prother 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Combination therapy with capecitabine an

Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: A phase II study

✍ Peeter Padrik; Krista Leppik; Andrus Arak 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 76 KB